(Q37858440)

24 August 2017

1 reference

title

Genetic profile of astrocytic and oligodendroglial gliomas (English)

1 reference

24 August 2017

1 reference

Hiroko Ohgaki

1

1 reference

24 August 2017

Paul Kleihues

series ordinal

2

1 reference

24 August 2017

publication date

26 March 2011

1 reference

24 August 2017

published in

Brain Tumor Pathology

1 reference

24 August 2017

volume

28

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

177-183

1 reference

Molecular Classification of Low-Grade Diffuse Gliomas

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Genetic pathways to primary and secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Genetic pathways to glioblastoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Correlation among pathology, genotype, and patient outcomes in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Molecular signatures classify astrocytic gliomas by IDH1 mutation status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-011-0029-1

10.1007/S10014-011-0029-1

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference